OR WAIT 15 SECS
The company announced that it has completed its 100th program using the pAVEway protein expression system, which was originally introduced to the market in 2007.
On June 20, 2017, FUJIFILM Diosynth Biotechnologies announced the completion of its 100th program using pAVEway Advanced Protein Expression system. The expression system was originally introduced to the market during the 2007 BIO International Convention in Boston, Massachusetts.
pAVEway was developed by FUJIFILM Diosynth Biotechnologies to enable the reliable and scalable GMP manufacturing of E.coli -based processes. The pAVEway system has the ability to control protein expression by allowing expression and secretion to be coupled. It also allows for slower expression, which can result in a higher chance of folding, and to sustain accumulation for many hours with continued cell growth. The system is suited to investigate difficult-to-express proteins with protein toxicity to the cells.